Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19

    NEXT STORY
    Survey: Still Not Enough Americans Willing to Take COVID-19 Vaccines to Achieve Herd Immunity
    PREV STORY
    Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Cara Therapeutics Announces Positive Data From Quantitative Phase 1 Trial Measuring Respiratory Safety of I.V. CR845

    STAMFORD, Conn., April 24, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical ...

    author_avatar
    NASDAQ Market News

    Guardant Health Receives Expanded Medicare Coverage for Guardant360 Across the Vast Majority of Solid Tumor Cancers

    author_avatar
    NASDAQ Market News

    ZIOPHARM Announces Three Presentations at the 2017 Annual Meeting of the Society for Neuro-Oncology

    BOSTON, Oct. 12, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company ...

    author_avatar
    NASDAQ Market News